Exelixis (NASDAQ: EXEL) reported Q3 EPS of $0.26, $0.18 better than the analyst estimate of $0.08. Revenue for the quarter came in at $152.5 million versus the consensus estimate of $104.89 million.

2017 Financial Guidance

The company is updating its guidance that total costs and operating expenses for the full year will be between $285 million and $295 million. This guidance includes approximately $25 million of non-cash costs and expenses related primarily to stock-based compensation expense.

For earnings history and earnings-related data on Exelixis (EXEL) click here.